BHST revenueFY2025$34.51M
- FY YoY
- +37.0%
BHST revenue was $34.51M for fiscal 2025 (ended Dec 31, 2025), up 37.0% from fiscal 2024.
BioHarvest Sciences Inc. (BHST) financials
For fiscal 2025 (ended Dec 31, 2025), BioHarvest Sciences Inc. reported $34.51M of revenue and -$11.13M of net income.
- Revenue, FY2025
- $34.51M
- Revenue growth, YoY
- +37.0%
- Net income, FY2025
- -$11.13M
- Net margin
- -32.3%
- Free cash flow, FY2025
- -$9.58M
- Cash
- $23.02M
- P/S
- 1.04
- Market cap
- $36.0M
FY2023FY2025
FY2023FY2025
FY2023FY2025
BHST revenue and earnings growth
BHST net incomeFY2025-$11.13M
BHST net income was -$11.13M for fiscal 2025 (ended Dec 31, 2025), compared with -$12.91M in fiscal 2024.
BHST free cash flowFY2025-$9.58M
BHST free cash flow was -$9.58M for fiscal 2025 (ended Dec 31, 2025), compared with -$9.52M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Revenue | $34.51M | $25.19M | $12.67M |
| Cost of revenue | $14.03M | $11.25M | $7.04M |
| Gross profit | $20.48M | $13.94M | $5.63M |
| Research and development | $5.31M | $4.80M | $3.37M |
| Selling, general and admin | $4.93M | $4.40M | $4.48M |
| Operating income | -$5.58M | -$6.99M | -$9.97M |
| Pre-tax income | -$11.06M | -$12.90M | -$12.56M |
| Income tax | -$76.0K | -$8.0K | $0 |
| Net income | -$11.13M | -$12.91M | -$12.56M |
| EPS, basic | -$0.60 | -$0.80 | -$0.93 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $23.02M | $2.39M | $5.36M |
| Receivables | $1.98M | $1.12M | $808.0K |
| Inventory | $4.56M | $3.65M | $2.47M |
| Current assets | $30.50M | $7.86M | $9.05M |
| Total assets | $47.66M | $25.00M | $15.00M |
| Current liabilities | $7.68M | $14.26M | $26.47M |
| Short-term debt | $149.0K | $3.90M | $0 |
| Total liabilities | - | $23.67M | $29.86M |
| Shareholders' equity | $25.45M | $1.33M | -$14.85M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | -$7.23M | -$6.68M | -$8.52M |
| Capital expenditures | $2.35M | $2.83M | $1.47M |
| Free cash flow | -$9.58M | -$9.52M | -$10.00M |
| Investing cash flow | -$2.37M | -$3.03M | -$1.47M |
| Financing cash flow | $30.19M | $6.78M | $13.56M |
| Depreciation and amortization | $1.62M | $1.25M | $840.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Revenue growth, YoY | 37.0% | 98.8% | - |
| Gross margin | 59.3% | 55.4% | 44.5% |
| Operating margin | -16.2% | -27.7% | -78.6% |
| Net margin | -32.3% | -51.3% | -99.1% |
| Free cash flow margin | -27.8% | -37.8% | -78.9% |
| Return on equity | -43.8% | -970.9% | - |
| Return on assets | -23.4% | -51.6% | -83.7% |
| Current ratio | 3.97 | 0.55 | 0.34 |
Source: XBRL data BioHarvest Sciences Inc. files with the SEC, latest filing dated Mar 31, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
BHST FAQ
8 questionsWhat is BHST revenue?
BioHarvest Sciences Inc. (BHST) reported $34.51M of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 37.0% from the year before.Is BHST profitable?
No. BioHarvest Sciences Inc. reported a net loss of $11.13M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does BHST have?
BioHarvest Sciences Inc. reported $23.02M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is BHST revenue growing?
BioHarvest Sciences Inc.'s revenue changed +37.0% in fiscal 2025, to $34.51M.What is BHST gross margin?
BioHarvest Sciences Inc.'s gross profit was $20.48M on $34.51M of revenue for fiscal 2025 (ended Dec 31, 2025), a gross margin of 59.3%.What is BHST free cash flow?
BioHarvest Sciences Inc. generated -$9.58M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$7.23M less capital expenditures.When did BHST last report financial results?
The latest statements here come from BioHarvest Sciences Inc.'s 40-F filed on Mar 31, 2026, covering the period ended Dec 31, 2025.Where does this BHST financial data come from?
Quantisnow builds these statements from the structured XBRL data BioHarvest Sciences Inc. files with the SEC. It is provided for information only and is not investment advice.